Mirion delivers vital protection that unlocks the transformative potential of radiation to move science, industry and medicine forward.

The company generates revenue by selling radiation detection, measurement and monitoring products, software and related services directly and indirectly to a broad range of end use customers, including nuclear power operators, research laboratories, defense agencies, hospitals and cancer centers.

The company operates through the following segments: Nuclear & Safety and Medical.

• Nuclear & Safety: This segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across nuclear power facilities, laboratories, research sites and industrial markets such as defense, providing radiation monitoring systems, reactor instrumentation, imaging equipment, waste management solutions and laboratory analysis tools.

• Medical: This segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety, offering radiation therapy quality assurance hardware and software, nuclear medicine products for radiopharmaceutical production and patient dosing, and occupational dosimetry services that monitor radiation exposure for healthcare workers.

Mirion holds a leading position in the radiation safety industry, benefiting from a large installed base of its products in more than 98% of global nuclear power plants and over 80% of cancer centers worldwide, which creates recurring revenue through replacement, service and upgrade cycles; key competitors in the Nuclear & Safety segment include Thermo Fisher Scientific, Curtiss Wright, Ortec (Ametek), FLIR (Teledyne), Ludlum, Fuji Electric, Caen System, Fluke (Fortive), Berthold Technologies, and Framatome, while the Medical segment faces competition from Landauer (Fortive), PTW, IBA, Standard Imaging, Comecer, and LAP.

The company serves a diverse customer base that includes active nuclear power reactors, developers of small modular reactors, universities, numerous international government and supranational agencies, 23 of the 32 NATO militaries, national laboratories, environmental laboratories, research institutes, industrial companies, radiopharmaceutical drug manufacturers, hospitals, cancer centers, and small office healthcare providers.